by CARLA K. JOHNSON
The compound in psychedelic mushrooms helped heavy drinkers scale back or quit entirely in probably the most rigorous test of psilocybin for alcoholism.
More research is required to see if the result lasts and whether it works in a more substantial study. Many who took a dummy drug rather than psilocybin also succeeded in drinking less, likely because all study participants were highly motivated and received talk therapy.
Psilocybin, within several species of mushrooms, could cause hours of vivid hallucinations. Indigenous folks have used it in healing rituals and scientists are exploring whether it could ease depression or help longtime smokers quit. It’s illegal in the U.S., though Oregon and many cities have decriminalized it. Starting next year, Oregon allows its supervised use by licensed facilitators.
The brand new research, published Wednesday in JAMA Psychiatry, is “the initial modern, rigorous, controlled trial” of whether additionally, it may help people fighting alcohol, said Fred Barrett, a Johns Hopkins University neuroscientist who wasn’t mixed up in study.
In the analysis, 93 patients took a capsule containing psilocybin or perhaps a dummy medicine, lay on a couch, their eyes covered, and paid attention to recorded music through headphones. They received two such sessions, a month apart, and 12 sessions of talk therapy.
Through the eight months after their first dosing session, patients taking psilocybin did much better than another group, drinking heavily on about 1 in 10 days typically vs. about 1 in 4 days for the dummy pill group. Almost half who took psilocybin stopped drinking entirely weighed against 24% of the control group.
Only three conventional drugsdisulfiram, naltrexone and acamprosateare approved to take care of alcohol use disorder and there has been no new drug approvals in nearly 20 years.
While it isn’t known just how psilocybin works in the mind, researchers believe it does increase connections and, at the very least temporarily, changes what sort of brain organizes itself.
“More elements of the mind are speaking with more elements of the mind,” said Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine, who led the study.
Less is well known about how exactly enduring those new connections may be. In theory, coupled with talk therapy, people could probably break bad habits and adopt new attitudes easier.
“There is a chance for really shifting in a comparatively permanent way the functional organization of the mind,” Bogenschutz said.
Patients described life-changing insights that gave them lasting inspiration, Bogenschutz said.
Mary Beth Orr, 69, of Burien, Washington, said her psilocybin-induced hallucinationsflying over breathtaking landscapes and merging telepathically with creative people throughout historytaught her she wasn’t alone.
Before searching for the analysis in 2018, Orr had five or six drinks each night and much more on weekends.
“The number was unacceptable yet I couldn’t stop,” she said. “There is no off switch that I possibly could access.”
During her first psilocybin experience, she saw a vision of her late father, who gave her a couple of eagle eyes and said, “Go.” She told the therapists monitoring her: “These eagle eyes can’t see God’s face, however they know where it really is.”
She stopped drinking entirely for just two years, and today comes with an occasional glass of wine. A lot more than the talk therapy, she credits psilocybin.
“It made alcohol irrelevant and uninteresting if you ask me,” Orr said. Now, “I’m tethered to my children and my family members in a manner that just precludes the need to be alone with alcohol.”
Patients receiving psilocybin had more headaches, nausea and anxiety than those obtaining the dummy drug. One individual reported thoughts of suicide throughout a psilocybin session.
Within an experiment such as this, it is important that patients have no idea or guess should they got the psilocybin or the dummy drug. To attempt to accomplish that, the researchers opt for generic antihistamine with some psychoactive effects because the placebo.
Still, most patients in the analysis correctly guessed if they got the psilocybin or the dummy pill.
Paul Mavis couldn’t guess. The 61-year-old from Wilton, Connecticut, got the placebo, but nonetheless quit drinking. To begin with, the talk therapy helped, telling him that his emotional life stalled at age 15 when he started drinking to feel numb.
And he described a life-changing moment throughout a session where he was taking the dummy drug: He imagined the death of someone you care about. Suddenly, a rigorous, incapacitating grief overcame him.
“I was crying, which isn’t typical for me personally. I was sweating. I was bereft,” he said. “As I’m attempting to reconcile this grief, like, why am I feeling this?
“Instantly, I thought, ‘Drinking equals death.'” He said he hasn’t had a glass or two since.
Dr. Mark Willenbring, former director of treatment research at the National Institute for Alcohol Abuse and Alcoholism, said more research is necessary before psilocybin can be viewed as a highly effective addition to talk therapy. He noted that talking with a therapist helped both groupsthose who got psilocybin and the ones who didn’tand the added advantage of psilocybin seemed to wear off as time passes.
“It’s tantalizing, absolutely,” Willenbring said. “Is more research required? Yes. Could it be ready for prime time? No.”
More info: Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the treating Adult Patients With Alcohol Use Disorder, JAMA Psychiatry (2022). DOI: 10.1001/jamapsychiatry.2022.2096
2022 The Associated Press. All rights reserved. This material might not be published, broadcast, rewritten or redistributed without permission.
Citation: ‘Magic mushroom’ psychedelic can help heavy drinkers quit (2022, August 27) retrieved 27 August 2022 from https://medicalxpress.com/news/2022-08-magic-mushroom-psychedelic-heavy-drinkers.html
This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.